OakChart

Gyre Therapeutics Inc

GYREHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

4.26+0.03 (0.71%)
2026-11-12 03:22 CET
Market cap
451.70 USD m
Revenue, TTM
121.75 USD m
Net income, TTM
-26.13 USD m
Free cash flow, TTM
-24.72 USD m
EPS diluted, TTM
-0.27
P/E
-
Compare

Price

GYRE against its 20, 50 and 200-day averages
2050200beatmiss
4.005.006.007.00600K1.2MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26GYREclose 4.2620-day 5.4350-day 6.38200-day 6.854.2652w low

53.4% under the 52-week high of 9.14 on 5 Mar 2026. 52-week low 3.97 on 5 Nov 2026. Last 15 sessions, 78.8% high to low

Volume 0.87× normal · the line is the 50-bar volume average

Profile

GYRE
52-week range, 6% of the way up
3.979.14

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The firm operates two distinct segments: Gyre Pharmaceuticals and Gyre. The Gyre Pharmaceuticals segment extends three major commercial drug products including ETUARY, Etorel, and Contiva as well as several product candidates in preclinical and clinical development. The Gyre segment consists of the development and commercialization of Hydronidone for the treatment of metabolic dysfunction-associated steatohepatitis associated liver fibrosis. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.

IndexRUT
Employees625
IPOApr 12, 2006
Beta1.98
ATR, 14d0.46
Rel volume0.87
Short float8.71%
Insider own77.69%
Inst own4.98%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap491.27M
Enterprise Value482.35M
Income-26.13M
Sales121.75M
Book/sh1.01
Cash/sh0.61
Dividend Est.-
Dividend TTM-
Dividend Ex-DateJan 13, 2023
Dividend Gr. 3/5Y- -
Payout0.00%
Employees625
IPOApr 12, 2006

Ratios

P/E-
Forward P/E-
PEG-
P/S4.04
P/B4.23
P/C7.01
P/FCF-
EV/EBITDA-
EV/Sales3.96
Quick Ratio3.70
Current Ratio4.32
Debt/Eq0.02
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.27
EPS next Y-0.33
EPS next Q-0.07
EPS this Y-1566.66%
EPS next Y-12.50%
EPS next 5Y-
EPS past 3/5Y-63.33% -
Sales past 3/5Y4.46% 40.96%
EPS Y/Y TTM-458.42%
Sales Y/Y TTM13.51%
EPS Q/Q-209.17%
Sales Q/Q7.75%
EarningsNov 05 AMC
EPS/Sales Surpr.65.72% 15.96%

Ownership

Insider Own77.69%
Insider Trans-0.17%
Inst Own4.98%
Inst Trans9.14%
ROA-13.90%
ROE-21.67%
ROIC-19.08%
Gross Margin94.15%
Oper. Margin-18.08%
Profit Margin-21.46%
SMA20-21.49%
SMA50-33.26%
SMA200-37.79%
Trades-

Technical

Shs Outstand107.07M
Shs Float25.73M
Short Float8.71%
Short Ratio14.89
Short Interest2.24M
52W High9.14 -53.39%
52W Low3.97 7.30%
Volatility10.12% 9.36%
ATR (14)0.46
RSI (14)34.58
Beta1.98
Rel Volume0.87
Avg Volume150.51K
Volume130,511

Performance

Perf Week-4.05%
Perf Month-36.51%
Perf Quarter-34.86%
Perf Half Y-41.48%
Perf YTD-39.66%
Perf Year-46.82%
Perf 3Y-51.03%
Perf 5Y-40.64%
Perf 10Y-84.02%
Recom1.00
Target Price18.67
Prev Close4.23
Price4.26
Change %0.71%

Analyst ratings

latest 10 of 14
DateActionAnalystRating changeTargetImplied
Oct 10, 2025InitiatedJJefferiesBuy$16+275.6%
Aug 26, 2025InitiatedHH.C. WainwrightBuy$18+322.5%
Mar 11, 2025InitiatedNNoble Capital MarketsOutperform
Apr 29, 2021ResumedSStephensOverweight$18 → $19+346.0%
Feb 10, 2021InitiatedPPiper SandlerOverweight$15+252.1%
May 21, 2020InitiatedRRaymond JamesOutperform$20+369.5%
Jan 04, 2019InitiatedOOppenheimerOutperform$24+463.4%
Feb 12, 2018ReiteratedBB. Riley FBR, Inc.Buy$19 → $49+1,050.2%
Feb 09, 2018ReiteratedCChardan Capital MarketsBuy$37.50 → $75+1,660.6%
Feb 09, 2018ReiteratedCChardan Capital MarketsBuy$10 → $75+1,660.6%

Peers

Mkt cap
TickerCompanyMkt cap
GALTGalectin Therapeutics Inc331.79M
IVAInventiva ADR958.79M
SGMTSagimet Biosciences Inc802.60M
ALTAltimmune Inc375.41M
AVLNAvalyn Pharma Inc1.40B
MDGLMadrigal Pharmaceuticals Inc10.06B
PLRXPliant Therapeutics Inc48.15M
AAPGAscentage Pharma Group International ADR1.40B
VCREVicore Pharma Holding AB ADR318.49M
MTVAMetaVia Inc9.49M

Insider trading

latest 14 of 36
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Ye WeiguoChief Operating OfficerJun 10 '26Option Exercise0.755,0003,750705,000Jun 22 04:02 PM
Ye WeiguoChief Operating OfficerJun 09 '26Option Exercise0.753,0002,250703,000Jun 22 04:02 PM
Ye WeiguoChief Operating OfficerJun 18 '26Option Exercise0.753,0002,250703,000Jun 22 04:02 PM
Ye WeiguoChief Operating OfficerJun 10 '26Sale6.245,00031,200700,000Jun 22 04:02 PM
Ye WeiguoChief Operating OfficerJun 18 '26Sale6.353,00019,050700,000Jun 22 04:02 PM
Ye WeiguoChief Operating OfficerJun 09 '26Sale6.153,00018,450700,000Jun 22 04:02 PM
Ye WeiguoChief Operating OfficerJun 11 '26Option Exercise0.752,8002,100702,800Jun 15 04:01 PM
Ye WeiguoChief Operating OfficerJun 11 '26Sale6.172,80017,276700,000Jun 15 04:01 PM
Ye WeiguoChief Operating OfficerJun 09 '26Option Exercise0.7514,50010,875714,500Jun 11 04:01 PM
Ye WeiguoChief Operating OfficerJun 10 '26Option Exercise0.756,4184,814706,418Jun 11 04:01 PM
Ye WeiguoChief Operating OfficerJun 09 '26Sale6.1414,50089,030700,000Jun 11 04:01 PM
Ye WeiguoChief Operating OfficerJun 10 '26Sale6.216,41839,856700,000Jun 11 04:01 PM
Ye WeiguoChief Operating OfficerJun 04 '26Option Exercise0.7519,57514,681719,575Jun 08 04:01 PM
Ye WeiguoChief Operating OfficerJun 05 '26Option Exercise0.7515,40111,551715,401Jun 08 04:01 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWMiShares Russell 2000 Index FundAUM: 77.38B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
EESWisdomTree U.S. SmallCap FundAUM: 684.87M
SCHBSchwab U.S. Broad Market ETFAUM: 44.09B

News

latest 14 of 200
  • Gyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business Updates (GlobeNewswire) -9.68% +18.70%
  • Gyre Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
  • Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update (GlobeNewswire)
  • Gyre Therapeutics Appoints Three New Members to its Board of Directors (GlobeNewswire) -5.76%
  • Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment (GlobeNewswire)
  • Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update (GlobeNewswire) -12.06%
  • Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company (GlobeNewswire)
  • Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment (GlobeNewswire)
  • Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire) -6.30%
  • ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
  • Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue Estimates (Zacks) +5.84%
  • Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction (TipRanks) -9.82%
  • Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
  • Gyre Therapeutics Announces Alignment with China's CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting (GlobeNewswire) +16.30%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.040-0.117-0.04032.9328.403
2026Q22026-08-07-0.120-0.057-0.11629.1126.493
2026Q12026-05-07-0.100-0.073-0.09622.5231.613
2025Q42026-03-12-0.0200.057-0.01937.2035.433
2025Q32025-11-070.0300.0470.03530.5632.933
2025Q22025-08-110.0000.0300.00226.7730.801
2025Q12025-05-090.0000.0300.00422.0628.401
2024Q42025-03-170.0000.040-0.00327.8723.501
2024Q32024-11-130.010-0.01325.49--
2024Q22024-08-130.010-0.03425.23--
2024Q12024-05-090.030-0.07327.17--
2023Q22023-08-03-1.050-1.050-0.9810.000.001
2022Q42023-04-05-19.050-1.575-16.0720.000.402
2022Q32022-11-23-2.400-1.500-2.3270.000.001
2022Q22022-08-1524.600-3.67524.6000.000.002
2022Q12022-05-09-6.900-6.851-6.9320.790.803

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-69.000-49.350-68.9470.0015.00
2020FY-43.950-40.463-43.98620.9518.97
2021FY-43.050-42.113-43.0477.345.07
2022FY-3.90013.8000.4560.801.00
2023FY-1.410--1.412113.45-
2024FY0.0500.1700.048105.76101.39
2025FY0.0200.1630.020116.59114.83
2026FY--0.293--112.63
2027FY--0.330--147.2
2028FY-1.670--450.8
2029FY-0.280--279.1
2030FY-0.380--323

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0631129.5125.4433.80
2026Q4S2026-10-2130029.5329.3030.00
2026Q4S2026-08-0733029.5329.3030.00
2026Q4S2026-07-2130026.7323.0028.70
2026Q4S2026-05-0732126.7323.0028.70
2026Q4S2026-03-1230137.3027.9056.00
2026Q4S2026-03-0320142.7529.5056.00
2026Q4S2026-01-2120044.2032.4056.00
2026Q4S2025-11-1120144.2032.4056.00
2026Q4S2025-11-1020144.2032.4056.00
2026Q4S2025-11-0920144.2032.4056.00
2026Q4S2025-11-0820144.2032.4056.00
2026Q4S2025-11-0720144.2032.4056.00
2026Q4S2025-11-0620049.2532.4066.10

Estimate history

EPS, annual-111.767-40.202-68.947-43.986-43.0470.456-1.4120.0480.023-0.269
Period201720182019202020212022202320242025TTM
EPS, quarterly0.013-0.0030.0040.0020.035-0.019-0.096-0.116-0.038
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual1.0180.006020.9487.338102.29113.45105.757116.588121.75
Period201720182019202020212022202320242025TTM
Sales, quarterly25.48827.87222.05826.77130.56437.19522.51929.10532.934
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.4050.7970.8031.4732.0944.23976.59686.30891.314107.069
Period201720182019202020212022202320242025MRQ
Shares, quarterly85.7786.30887.63690.82390.8991.31491.337106.034107.069
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue121.75116.59105.76113.45102.297.3420.950.000.01
Cost of Goods Sold Incl. D&A7.135.423.884.644.797.679.300.150.15
Gross Profit114.63111.17101.87108.8197.50-0.3311.65-0.15-0.14
Selling, General and Administrative Excl. Other136.6499.6885.6489.6088.2983.3969.0257.1333.68
Research and Development39.2013.7012.0213.7816.6964.5752.8443.8621.47
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-22.0111.4916.2319.219.20-83.73-57.37-57.28-33.82
Interest Expense0.000.000.000.000.000.000.000.000.00
Unusual Expense2.94-2.71-7.1795.060.004.170.00--
Net Income Before Taxes-25.4814.4423.22-76.979.41-87.93-56.24-55.18-30.05
Income Taxes2.494.565.328.525.100.000.000.000.00
Consolidated Net Income-27.979.8817.90-85.484.31-87.93-56.24-55.18-30.05
Net Income From Continuing Operations-25.075.0312.09-92.932.30-87.93-56.24-55.18-30.05
Net Income-26.135.0312.09-92.932.30-87.93-56.24-55.18-30.05
EPS (Recurring)-0.230.00-0.00-0.400.46-41.62-43.99-68.95-40.20
EPS (Basic, Before Extraordinaries)-0.270.060.14-1.410.54-43.05-43.99-68.95-40.20
EPS (Diluted)-0.270.020.05-1.410.46-43.05-43.99-68.95-40.20
EBITDA-18.6614.0117.8220.3310.33-83.44-57.23-57.13-33.67
Non-Operating Income (Expense)-0.530.24-0.18-1.110.21-0.041.132.103.77
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.495.650.665.7510.563.403.633.202.58
Price To Earnings Ratio----0.43----
Price To Sales Ratio6.406.2511.7014.910.393.825.78-14,746.26
Gross Margin94.1595.3596.3395.9195.31-4.5255.60--2,383.33
Operating Margin-18.089.8615.3516.949.00-1,140.99-273.87--563,700.00
Net Margin-21.464.3111.43-81.922.25-1,198.32-268.48--500,916.67
Shares Outstanding107.0791.3186.3176.604.242.091.470.800.80
Market Capitalization451.70451.701,038.451,967.435.142.3411.356.677.67

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue32.9329.1122.5237.2030.5626.7722.0627.87
Cost of Goods Sold Incl. D&A1.952.211.231.741.631.150.891.18
Gross Profit30.9926.9021.2935.4528.9425.6221.1626.70
Selling, General and Administrative Excl. Other32.4640.7628.0935.3322.0123.4518.8926.03
Research and Development8.5119.146.744.822.363.423.103.71
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-1.47-13.86-6.800.126.932.172.270.66
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.360.372.46-0.260.02-0.21-2.25-0.19
Net Income Before Taxes-1.75-14.43-9.24-0.077.632.244.630.77
Income Taxes0.73-0.160.621.301.690.660.900.20
Consolidated Net Income-2.48-14.27-9.86-1.375.941.583.730.57
Net Income From Continuing Operations-4.05-10.61-8.69-1.723.610.442.70-0.10
Net Income-4.05-11.66-8.69-1.723.610.442.70-0.10
EPS (Recurring)-0.04-0.11-0.08-0.020.040.00-0.01-0.00
EPS (Basic, Before Extraordinaries)-0.04-0.12-0.10-0.020.040.010.03-0.00
EPS (Diluted)-0.04-0.12-0.10-0.020.030.000.00-0.00
EBITDA-0.97-12.38-6.130.817.582.812.811.13
Non-Operating Income (Expense)0.09-0.200.03-0.450.73-0.150.11-0.09
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.371.452.043.630.910.720.400.45
Price To Earnings Ratio--308.41185.30457.67153.4464.77-
Price To Sales Ratio6.405.565.445.527.237.397.829.83
Gross Margin94.0992.4194.5595.3194.6795.7095.9595.78
Operating Margin-4.46-47.62-30.210.3222.668.1110.302.38
Net Margin-12.31-40.07-38.59-4.6311.811.6512.23-0.36
Shares Outstanding107.07106.0391.3491.3190.8990.8287.6486.31
Market Capitalization451.70734.71636.46641.69677.57663.88666.481,038.45

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments52.4226.6733.5125.1846.8579.3576.86120.1837.78
Short Term Receivables36.9529.1516.8417.141.823.3115.000.000.00
Inventories10.176.344.286.120.000.000.000.000.00
Other Current Assets2.832.622.591.222.816.844.203.811.33
Total Current Assets102.3764.7957.2249.6551.4889.5196.07123.9939.11
Net Property, Plant & Equipment26.1627.1325.2719.933.712.272.230.390.28
Total Investments and Advances25.1226.270.000.000.002.540.000.000.00
Long-Term Note Receivable-0.004.720.00-----
Intangible Assets4.730.270.200.30----0.00
Deferred Tax Assets6.875.624.704.08-----
Other Assets0.891.3324.4310.790.470.530.260.540.13
Total Assets166.13125.41116.5484.7555.6694.8598.55124.9239.51
Short Term Debt Incl. Current Port. of LT Debt0.640.710.210.491.980.660.480.005.08
Accounts Payable0.120.110.350.126.425.934.281.250.75
Income Tax Payable2.942.835.052.10-----
Other Current Liabilities14.5915.8614.439.535.7711.2024.143.552.91
Total Current Liabilities18.2919.5220.0512.2414.1617.8028.904.808.74
Long Term Debt0.300.890.200.120.410.981.320.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities4.416.6017.820.170.000.000.000.170.00
Total Liabilities23.0027.0038.0612.5414.5718.7830.224.978.74
Non-Equity Reserves0.850.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.0064.530.000.000.000.000.000.00
Common Equity106.0363.32-15.8342.5241.0976.0768.34119.9430.77
Total Shareholders Equity106.0363.3248.7042.5241.0976.0768.34119.9430.77
Accumulated Minority Interest36.2535.0829.7829.700.000.000.000.000.00
Total Equity142.2898.4078.4772.2241.0976.0768.34119.9430.77
Total Liabilities & Stockholders Equity166.13125.41116.5484.7555.6694.8598.55124.9239.51
Book Value Per Share1.160.73-0.2110.0319.6251.6485.13150.5075.91
Tangible Book Value Per Share1.110.73-0.219.9619.6251.6485.13150.5075.91
Full-Time Employees6255474556342113
Price to Book Ratio4.2316.43-2.300.170.060.150.100.060.19
Return on Assets3.459.99-128.203.28-116.85-58.16-49.38-36.56-55.57
Return on Equity5.9421.58-308.155.51-150.11-77.89-58.61-39.88-92.05
Return on Invested Capital4.7318.82-190.065.40-211.90-72.99-79.22-25.06-70.06
Quick Ratio5.042.992.643.563.635.033.3225.834.48
Current Ratio5.603.322.854.063.635.033.3225.834.48

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-36.699.8817.90-85.484.31-87.93-56.24-55.18-30.05
Depreciation3.322.521.591.111.130.290.140.150.15
Other Funds (Non Cash)13.463.79-6.97103.9613.873.403.633.202.72
Funds from Operations-22.9015.0811.5118.4318.47-84.24-52.48-51.83-27.18
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.25-15.55-15.697.46-7.800.48-2.578.21-1.37
Income Taxes Payable0.030.04-2.173.00-1.34----
Cash from Operating Activities-23.16-0.48-4.1825.8910.68-83.75-55.05-43.61-28.55
Capital Expenditures-2.68-1.92-3.13-8.59-5.00-0.84-0.27-0.06-0.38
Net Assets From Acquisitions0.000.000.00-0.690.000.000.000.00-
Sale of Fixed Assets and Businesses0.070.030.400.660.000.000.000.00-
Purchase or Sale of Investments12.891.42-17.16-1.00-1.3349.039.9327.46-70.94
Purchase of Investments-23.09-14.01-17.16-1.00-1.330.00-97.64-129.98-198.91
Sale Or Maturity of Investments35.9815.430.000.000.0049.03107.56157.43127.97
Other Uses0.000.000.00-15.73-7.480.000.000.000.00
Other Sources0.000.000.005.590.000.000.000.000.00
Cash from Investing Activities10.28-0.47-19.88-19.76-13.8148.199.6627.39-71.32
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.7625.862.642.500.0049.5560.380.33116.41
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.7625.862.642.500.0049.5560.380.33116.41
Proceedsfrom Stock Options-0.5123.000.000.000.0049.2559.940.00106.87
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.00-5.08
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.210.000.000.000.000.000.000.000.00
Other Financing Activities Uses-0.210.000.000.000.000.000.000.000.00
Cash from Financing Activities0.5525.862.642.500.0049.5560.380.33111.33
Exchange Rate Effect1.440.34-0.27-0.30-1.89----
Net Change in Cash-10.8825.26-21.708.33-5.0313.9914.99-15.8911.46
Free Cash Flow-24.72-1.67-6.4917.385.69-84.59-55.31-43.68-28.93
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow---97.347.01----
Deferred Taxes & Investment Tax Credit--1.11-1.00-1.16-0.840.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments70.0474.8049.8152.4260.0554.37
Short Term Receivables35.0229.4626.8136.9526.8025.36
Inventories17.4917.3111.3510.178.858.86
Other Current Assets0.850.513.762.832.872.70
Total Current Assets123.40122.0791.73102.3798.5891.28
Net Property, Plant & Equipment29.9030.5625.9726.1624.9124.90
Total Investments and Advances30.3730.0431.0225.1222.0223.23
Intangible Assets4.404.534.634.734.854.96
Deferred Tax Assets10.139.287.726.876.716.13
Other Assets3.052.770.940.892.322.14
Total Assets201.25199.25162.01166.13159.38152.65
Short Term Debt Incl. Current Port. of LT Debt1.141.390.750.640.630.62
Accounts Payable2.641.240.270.120.560.07
Income Tax Payable2.832.153.132.942.651.08
Other Current Liabilities21.9823.8915.6414.5912.0915.14
Total Current Liabilities28.5928.6619.7918.2915.9116.92
Long Term Debt1.872.030.070.300.540.77
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities3.172.814.334.415.525.51
Total Liabilities33.6333.5124.1923.0021.9723.20
Non-Equity Reserves1.550.830.840.850.000.00
Preferred Stock - Carrying Value21.5522.430.000.000.000.00
Common Equity107.95107.93101.31106.03101.9292.03
Total Shareholders Equity129.50130.36101.31106.03101.9292.03
Accumulated Minority Interest36.5634.5635.6836.2535.4937.42
Total Equity166.07164.92136.99142.28137.41129.44
Total Liabilities & Stockholders Equity201.25199.25162.01166.13159.38152.65
Book Value Per Share1.011.021.111.161.121.01
Tangible Book Value Per Share0.970.981.061.111.070.96
Full-Time Employees---625--
Price to Book Ratio4.235.946.006.307.369.46
Return on Assets-13.90-9.89-4.363.454.673.04
Return on Equity-21.67-15.66-7.515.948.065.47
Return on Invested Capital-3.09-8.01-8.57-1.623.520.48
Quick Ratio3.703.664.065.045.644.87
Current Ratio4.324.264.645.606.195.40

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-2.48-22.99-9.86-1.375.941.58
Depreciation0.471.480.670.690.650.64
Other Funds (Non Cash)3.631.643.594.601.39-1.22
Funds from Operations0.88-21.29-6.333.847.440.70
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-4.864.569.51-9.47-2.45-0.29
Income Taxes Payable0.64-1.020.140.261.540.51
Cash from Operating Activities-3.98-16.733.18-5.624.990.41
Capital Expenditures-1.07-1.29-0.18-0.14-0.68-0.28
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.050.010.010.010.000.02
Purchase or Sale of Investments2.7611.04-2.881.98-0.56-2.78
Purchase of Investments-2.92-4.96-12.95-2.26-0.56-2.78
Sale Or Maturity of Investments5.6815.9910.074.240.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities1.739.76-3.061.85-1.25-3.04
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)--0.000.000.000.00
Change in Capital Stock0.220.200.020.320.0524.03
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.220.200.020.320.0524.03
Proceedsfrom Stock Options0.000.000.00-0.510.0023.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.00-0.210.000.000.000.00
Other Financing Activities Uses0.00-0.210.000.000.000.00
Cash from Financing Activities0.22-0.010.020.320.0524.03
Exchange Rate Effect0.390.640.280.130.120.05
Net Change in Cash-1.64-6.340.43-3.333.9121.45
Free Cash Flow-4.96-16.993.00-5.774.320.15
Price to Free Cash Flow--372.98-744.36-

Revenue breakdown

Contiva2025: 5.52M
Etorel2025: 4.62M
Other Product2024: 748.00K 2025: 312.00K
Product2024: 105.01M 2025: 106.14M
United States2024: 105.76M 2025: 116.59M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-309.48%2.2M23.7M127.33K
2026-10-158.15%1.9M23.7M108.29K
2026-09-308.11%1.9M23.7M102.71K
2026-09-157.32%1.7M23.7M79.84K
2026-08-317.23%1.7M23.7M80.69K
2026-08-146.31%1.7M27.7M88.32K
2026-07-315.55%1.8M32.9M93.94K
2026-07-156.22%2.0M32.9M94.60K
2026-06-309.00%1.8M20.3M90.89K
2026-06-159.85%1.7M17.7M90.18K
2026-05-299.47%1.7M17.7M101.36K
2026-05-159.13%1.7M18.4M98.98K
2026-04-3011.95%1.6M13.2M92.78K
2026-04-1513.41%1.6M11.8M98.25K
2026-03-3112.92%1.5M11.8M102.25K
2026-03-1311.71%1.4M11.8M94.48K
2026-02-2711.43%1.3M11.8M78.35K
2026-02-1312.61%1.5M11.8M75.29K
2026-01-3012.08%1.4M11.8M75.29K
2026-01-1512.72%1.5M11.8M74.06K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.004.900.000.0000.000.000.0000.0000.000
call5.000.003.800.0020.7660.000.000.943-0.0890.001
call7.500.003.800.0021.9540.000.000.940-0.0980.001
call10.000.003.800.0022.7420.000.000.939-0.1030.001
call12.500.003.800.0023.3270.000.000.937-0.1070.001
call15.000.003.800.0023.7900.000.000.937-0.1110.001
put2.500.000.050.000.0000.000.000.0000.0000.000
put5.000.004.500.0020.6890.000.00-0.055-0.0880.001
put7.500.705.500.0011.7360.000.00-0.058-0.0960.001
put10.003.208.000.0012.7800.000.00-0.059-0.1010.001
put12.505.7010.500.0013.5320.000.00-0.060-0.1050.001
put15.008.2013.000.0014.1180.000.00-0.061-0.1080.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-228-KCurrent report2026-10-16SEC
2026-09-018-KCurrent report2026-09-01SEC
2026-08-31S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-268-KCurrent report2026-08-26SEC
2026-08-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-078-KCurrent report2026-08-07SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-043Initial statement of beneficial ownership of securities2026-08-01SEC
2026-08-043Initial statement of beneficial ownership of securities2026-08-01SEC
2026-08-03EFFECTEffectiveness filing by commission orderSEC
2026-07-168-KCurrent report2026-07-10SEC
2026-07-158-K/A2026-05-04SEC
2026-07-13S-3/ASEC
2026-06-304Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-304Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-304Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-304Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-304Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-304Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-23S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-168-KCurrent report2026-06-10SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-08SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-08SEC
2026-06-10S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-0600433.42K8
2026-0500519.45K10
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
FMR LLC5.57%
HSG Holding Ltd3.36%
BVF INC/IL2.47%
Fairmount Funds Management LLC2.46%
Venrock Adviser, LLC1.91%
Logos Global Management LP1.70%
FCPM III SERVICES B.V.1.50%
BALYASNY ASSET MANAGEMENT L.P.1.49%
Vestal Point Capital, LP1.46%
Opaleye Management Inc.1.18%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND0.74%
iShares Russell 2000 ETF0.35%
PGIM Jennison Health Sciences Fund0.29%
VANGUARD EXTENDED MARKET INDEX FUND0.21%
Fidelity Small Cap Index Fund0.18%
Fidelity Extended Market Index Fund0.15%
iShares Russell 2000 Growth ETF0.11%
VANGUARD RUSSELL 2000 INDEX FUND0.10%
Schwab U.S. Small-Cap ETF0.09%
Goldman Sachs Absolute Return Tracker Fund0.04%

OakChart. GYRE. Cached 15 minutes.